Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Forms Division to Develop microRNA Disease Biomarkers

Premium

Regulus Therapeutics this week announced today that it has established a new research and development division that will focus on the identification of miRNAs as disease biomarkers.

Called Regulus microMarkers, the new unit will further develop Regulus' technology for extracting, profiling, and analyzing miRNAs, the company said.

“We believe that with our technical expertise and know-how, we can enhance early drug discovery and development processes by identifying microRNAs as biomarkers of disease and strengthening our therapeutic programs, and our collaborators’ and strategic partners’ programs," Regulus President and CEO Kleanthis Xanthopoulos said in a statement.

In 2012, Regulus partnered with Biogen Idec to discover miRNAs that could serve as biomarkers for multiple sclerosis. In November, Regulus announced that it had hit a key milestone in that alliance, profiling over 400 serum samples from MS patients and comparing them against samples from healthy volunteers.

Regulus also recently disclosed that it had struck a similar deal with an unnamed pharmaceutical firm for an undisclosed indication.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.